174 related articles for article (PubMed ID: 8097688)
1. Nonlinear pharmacokinetics of cefadroxil in the rat.
García-Carbonell MC; Granero L; Torres-Molina F; Aristorena JC; Chesa-Jiménez J; Plá-Delfina JM; Peris-Ribera JE
Drug Metab Dispos; 1993; 21(2):215-7. PubMed ID: 8097688
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of five oral cephalosporins in calves.
Soback S; Ziv G; Kurtz B; Paz R
Res Vet Sci; 1987 Sep; 43(2):166-72. PubMed ID: 3317582
[TBL] [Abstract][Full Text] [Related]
3. Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice.
Shen H; Ocheltree SM; Hu Y; Keep RF; Smith DE
Drug Metab Dispos; 2007 Jul; 35(7):1209-16. PubMed ID: 17452417
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
5. Studies on the renal excretion mechanisms of cefadroxil.
Granero L; Gimeno MJ; Torres-Molina F; Chesa-Jiménez J; Peris JE
Drug Metab Dispos; 1994; 22(3):447-50. PubMed ID: 8070323
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses.
Barbhaiya RH
Biopharm Drug Dispos; 1996 May; 17(4):319-30. PubMed ID: 8743403
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice.
Trang JM; Prejean JD; James RH; Irwin RD; Goehl TJ; Page JG
Drug Metab Dispos; 1993; 21(1):189-93. PubMed ID: 8095218
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.
Choudhury R; Epemolu RO; Rai BL; Hider RC; Singh S
Drug Metab Dispos; 1997 Mar; 25(3):332-9. PubMed ID: 9172951
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
Zhong DF; Li K; Xu JH; Du Y; Zhang YF
Acta Pharmacol Sin; 2003 Mar; 24(3):256-62. PubMed ID: 12617776
[TBL] [Abstract][Full Text] [Related]
10. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the pharmacokinetics of dioscin in rat.
Li K; Tang Y; Fawcett JP; Gu J; Zhong D
Steroids; 2005 Jul; 70(8):525-30. PubMed ID: 15894036
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice.
Posada MM; Smith DE
Pharm Res; 2013 Nov; 30(11):2931-9. PubMed ID: 23959853
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of verproside after intravenous and oral administration in rats.
Park EJ; Lee HS; Oh SR; Lee HK; Lee HS
Arch Pharm Res; 2009 Apr; 32(4):559-64. PubMed ID: 19407974
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of (-)-carbovir in rats. Evidence for nonlinear elimination.
Brouwer KR; St Claire RL; Lagarde J; Patanella JE; Walsh JS; Miwa GT
Drug Metab Dispos; 1990; 18(6):1078-83. PubMed ID: 1981516
[TBL] [Abstract][Full Text] [Related]
19. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.
Jeong DW; Kim YH; Kim HH; Ji HY; Yoo SD; Choi WR; Lee SM; Han CK; Lee HS
Biopharm Drug Dispos; 2007 Mar; 28(2):51-7. PubMed ID: 17163409
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
